<HashMap><database>MetabolomicsWorkbench</database><file_versions><headers><Content-Type>application/xml</Content-Type></headers><body><files><Other>http://www.metabolomicsworkbench.org/rest/study/study_id/ST002126/mwtab</Other></files><type>primary</type></body><statusCode>OK</statusCode><statusCodeValue>200</statusCodeValue></file_versions><scores/><additional><omics_type>Metabolomics</omics_type><technology_type>EI</technology_type><technology_type>Mass Spectrometry</technology_type><species>Mus Musculus</species><full_dataset_link>http://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&amp;StudyID=ST002126</full_dataset_link><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig2.B, Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig2.K, Fig5J).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:HSC Basal or Ctrl, NR-treatment 8 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 1 h | Batch:1c | Note:[13C, 15N] AAs were used for AA uptake (Fig5M); unlabeled AAs and TCA substrate were used for total AA levels (Fig2.C, Fig5K) and TCA substrate levels (Fig5J).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 0 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 12 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><study_factor>Source_Name[gating]:Lin– Scal1+ c-Kit+ CD48– CD150+ (HSC) | Treatment:NR 8 weeks, 5 FU 2 weeks, [13C, 15N] AAs were incorporated for 24 h and subsequently washed out for 6 h | Batch:1d | Note:[13C, 15N] AA levels and [13C]TCA substrate levels in different time point were calculated for AA catabolism (Fig5.L).</study_factor><submitter_affiliation>Sun Yat-sen University</submitter_affiliation><tissue>Bone Marrow</tissue><sample_protocol>GC POSITIVE ION MODE.</sample_protocol><repository>MetabolomicsWorkbench</repository><metabolite_name>Proline, 2TBDMS</metabolite_name><metabolite_name>Tyrosine, 3TBDMS</metabolite_name><metabolite_name>[13C, 15N]Tyrosine, 3TBDMS</metabolite_name><metabolite_name>Isoleucine, 2TBDMS</metabolite_name><metabolite_name>Citrate</metabolite_name><metabolite_name>[13C]Fumatate</metabolite_name><metabolite_name>[13C, 15N]Glutamic acid, 3TBDMS</metabolite_name><metabolite_name>Alanine, 2TBDMS</metabolite_name><metabolite_name>L-Cysteine, 3TBDMS</metabolite_name><metabolite_name>[13C]Alpha_Ketoglutarate</metabolite_name><metabolite_name>[13C, 15N]Isoleucine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Methionine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Histidine, 3TBDMS</metabolite_name><metabolite_name>Glycine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Valine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Phenylalanine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Glycine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Lysine, 3TBDMS</metabolite_name><metabolite_name>Threonine, 3TBDMS</metabolite_name><metabolite_name>Aspartic acid, 3TBDMS</metabolite_name><metabolite_name>Alpha_Ketoglutarate</metabolite_name><metabolite_name>[13C, 15N]Leucine, 2TBDMS</metabolite_name><metabolite_name>Hydroxyproline, (E)-, 3TBDMS</metabolite_name><metabolite_name>Succinate</metabolite_name><metabolite_name>Methionine, 2TBDMS</metabolite_name><metabolite_name>Histidine, 3TBDMS</metabolite_name><metabolite_name>[13C, 15N]Serine, 3TBDMS</metabolite_name><metabolite_name>[13C]Malate</metabolite_name><metabolite_name>[13C, 15N]Alanine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Aspartic acid, 3TBDMS</metabolite_name><metabolite_name>Phenylalanine, 2TBDMS</metabolite_name><metabolite_name>Serine, 3TBDMS</metabolite_name><metabolite_name>[13C]Succinate</metabolite_name><metabolite_name>Malate</metabolite_name><metabolite_name>Glutamic acid, 3TBDMS</metabolite_name><metabolite_name>Leucine, 2TBDMS</metabolite_name><metabolite_name>Lysine, 3TBDMS</metabolite_name><metabolite_name>Fumatate</metabolite_name><metabolite_name>[13C, 15N]Threonine, 3TBDMS</metabolite_name><metabolite_name>[13C]Citrate</metabolite_name><metabolite_name>Valine, 2TBDMS</metabolite_name><metabolite_name>[13C, 15N]Proline, 2TBDMS</metabolite_name><metabolite_name>Glutamine, 3TBDMS</metabolite_name><data_protocol></data_protocol><name_synonyms>Amino Acid, Acid, amino acids, Amino acids, Aminokarbonsaeure, Aminosaeure, Aminocarbonsaeure, Amino acid, Cell., Acids, alpha-amino acids, alpha-amino acid, Amino, alpha-amino carboxylic acids</name_synonyms><sample_synonyms>iones., Ionen, ion, Ion, ions</sample_synonyms></additional><is_claimable>false</is_claimable><name>Amino acids and TCA substrates in hematopoietic cells (Part3)</name><description/><dates><publication></publication></dates><accession>ST002126</accession><cross_references><TAXONOMY>10090</TAXONOMY></cross_references></HashMap>